Delivra Corp (fka DLRVF)

[Wo]

Delivra Achieves Record Third Quarter 2018 Revenues
CNW Group
CNW GroupNovember 19, 2018, 7:00 AM EST

https://finance.yahoo.com/news/delivra-achieves-record-third-quarter-120000789.html?.tsrc=applewf

TORONTO , Nov. 19, 2018 /CNW/ - Delivra Corp. (TSXV: DVA - "Delivra" or the "Company") reported its financial results for the three and nine months ended September 30, 2018 . All figures are reported in Canadian dollars ($), unless otherwise indicated. Delivra's financial statements are prepared in accordance with International Financial Reporting Standards.

Highlights for the Third Quarter and Year-To-Date 2018:

Achieved record revenues of $1,670,077 for the quarter and $3,976,861 for the year-to-date, representing an 81% and 21% growth over the comparative periods, respectively;

Successfully launched two new LivReliefTM products during the quarter which have begun selling on retailer shelves, LivReliefTM Extra Strength Chronic Angry Pain Relief Cream and LivReliefTM Sports & Active Pain Relief Cream;

Re-branded and re-packaged the LivReliefTM family of products during the quarter, which is now available at retail stores;

Increased the number of retail locations currently selling LivReliefTM products from 5,200 stores at the beginning of the year to over 6,000 retail locations as of today;

Developed a revolutionary, proprietary topical cream base therapeutic, DelivraTMN, for molecules of cannabis, cannabis-like and opioids, for a safer more targeted and consistent delivery to patients afflicted with chronic pain and anxiety;

Positive results received on the ability to treat pain directly with a topical version of AdvilTM (ibuprofen). Testing for effects of joint pain and inflammation, topical Delivra-ibuprofen formulation offers long-term pain and swelling reduction compared to oral ibuprofen;

Signed a joint venture agreement with Intervivo Solutions for a ready to market sleep and anti-anxiety topical therapeutic cream for the animal health industry. Our expertise in formulation using our innovative delivery system platform combined with Intervivo's success in demonstrating pharmacokinetic, safety and efficacy data in clinically relevant canine and feline models provides a unique platform for rapid development of transdermal commercial products for the veterinary market;

Founder and CEO, Dr. Joseph Gabriele , received the Ernst & Young Entrepreneur of the Year 2018 Ontario award in the Health Care category; and

Due to recently received inquiries from a number of interested parties in relation to the Company`s proprietary transdermal delivery system platform, Delivra engaged Canaccord Genuity Corp. to act as exclusive financial advisor to review, identify, analyze and explore the range of strategic and other opportunities available to the Company within the cannabis and pharma industries. There can be no assurance that the Company will enter into any transaction, that there will be any change in the operation or ownership of the Company, or that the Company will take any other corporate action as a result of the review.